WMA says trial participants must have access to best treatment when a trial endsBMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7471.876-a (Published 14 October 2004) Cite this as: BMJ 2004;329:876
- Bryan Christie
The World Medical Association (WMA) has sought to clarify controversial ethical guidance that seeks to ensure that people who take part in a research trial benefit by getting the best available treatment when the trial ends.
Its annual general assembly held in Tokyo this week decided to issue a note of clarification to paragraph 30 of the Declaration of Helsinki, which is regarded as the world's most widely recognised source of ethical guidance on medical research involving human participants.
The WMA amended the Declaration four years ago in …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial